Business Context and Reporting Period
Company: RXi Pharmaceuticals Corporation (Note: Metadata listed "SELLAS Life Sciences" but filing text confirms RXi Pharmaceuticals).
Reporting Period: Quarterly period ended September 30, 2010 (Form 10-Q).
Business Overview: RXi is a development-stage biopharmaceutical company focused on RNA interference (RNAi) therapeutics. The company has generated no revenue since inception and is currently advancing product candidates in dermal anti-scarring and retinal disorders. It relies on equity financing, grants, and partnerships to fund operations.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2010 | Nine Months Ended Sep 30, 2010 | Balance Sheet (Sep 30, 2010) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(4,135,000) | $(10,162,000) | N/A |
| Operating Loss | $(3,719,000) | $(12,929,000) | N/A |
| Cash & Cash Equivalents | N/A | N/A | $2,836,000 |
| Short-term Investments | N/A | N/A | $5,996,000 |
| Total Current Assets | N/A | N/A | $9,166,000 |
| Total Current Liabilities | N/A | N/A | $6,274,000 |
| Stockholders' Equity | N/A | N/A | $3,288,000 |
| Cash Flow from Operations (9mo) | N/A | $(8,388,000) | N/A |
Note: All amounts in thousands unless otherwise specified.
Material Changes vs. Prior Period
- Net Loss Improvement (9 Months): Net loss decreased by $2.08 million (17%) compared to the nine months ended September 30, 2009. This improvement was driven primarily by a $1.77 million non-cash gain from the change in fair value of common stock warrants.
- Operating Expenses: Total operating expenses decreased slightly. Research and Development (R&D) expenses fell by $407,000 (6%) year-over-year for the nine-month period, largely due to timing of patent costs. General and Administrative (G&A) expenses increased by $108,000 (2%) due to higher headcount and professional fees, offset by lower non-cash stock compensation.
- Liquidity Position: Cash and cash equivalents decreased from $5.68 million at year-end 2009 to $2.84 million at September 30, 2010. However, the company purchased $5.99 million in short-term investments (U.S. Treasury Bills) during the period, increasing total liquid assets.
- Financing Activity: In March 2010, the company completed an offering raising approximately $15.2 million in net proceeds. Concurrently, it repurchased 675,000 shares from CytRx Corporation for approximately $3.85 million as required by a stock redemption agreement.
Outlook, Risks, and Management Commentary
- Liquidity Outlook: Management believes existing cash and short-term investments are sufficient to fund operations through at least the first half of fiscal 2011. The company also has access to a Standby Equity Distribution Agreement (SEDA) expiring January 30, 2011.
- Future Funding Needs: The company expects to incur significant operating losses for the foreseeable future. It will depend on third-party funding (equity sales, grants, partnerships) to maintain operations. Failure to secure funding could force a scale-back or termination of operations.
- Recent Grants: In November 2010 (subsequent to period end), the company was awarded four Therapeutic Discovery Project (TDP) grants totaling $978,000 to fund pre-clinical development of RNAi therapeutics.
- Risk Factors: Key risks include the inability to generate revenue, the need for additional capital, the volatility of warrant valuations impacting net income, and the inherent risks of drug development and regulatory approval.
- Unusual Items: Significant non-cash items include stock-based compensation ($3.46 million for the nine months) and changes in the fair value of warrants ($2.76 million gain for the nine months).
Investor Verification Checklist
- Cash Runway: Verify if the $8.8 million in total liquid assets (cash + short-term investments) is sufficient to meet the projected burn rate through the first half of 2011 as stated by management.
- Warrant Liability: Review the valuation assumptions (volatility, risk-free rate) for the $3.425 million warrant liability, as changes in stock price significantly impact reported net income/loss.
- Stock Redemption Obligation: Confirm the status of the remaining obligation to repurchase shares from CytRx upon the exercise of warrants issued in the 2010 offering.
- Grant Utilization: Monitor the receipt and utilization of the $978,000 in TDP grants awarded in November 2010.
- SEDA Availability: Assess the likelihood and terms of utilizing the remaining capacity under the Standby Equity Distribution Agreement before its January 2011 expiration.